Eiger BioPharmaceuticals, Inc. (EIGR): Price and Financial Metrics

Eiger BioPharmaceuticals, Inc. (EIGR): $6.45

-0.15 (-2.27%)

POWR Rating

Component Grades













Add EIGR to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where EIGR ranks best; there it ranks ahead of 63.71% of US stocks.
  • The strongest trend for EIGR is in Sentiment, which has been heading up over the past 179 days.
  • EIGR's current lowest rank is in the Quality metric (where it is better than 5.21% of US stocks).

EIGR Stock Summary

  • Of note is the ratio of Eiger BioPharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 12% of US stocks have a lower such ratio.
  • EIGR's price/sales ratio is 26.99; that's higher than the P/S ratio of 94.29% of US stocks.
  • Revenue growth over the past 12 months for Eiger BioPharmaceuticals Inc comes in at 111.42%, a number that bests 92.65% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Eiger BioPharmaceuticals Inc, a group of peers worth examining would be SQZ, MEIP, GLYC, CTMX, and WVE.
  • Visit EIGR's SEC page to see the company's official filings. To visit the company's web site, go to www.eigerbio.com.

EIGR Valuation Summary

  • EIGR's price/sales ratio is 48.1; this is 323.79% higher than that of the median Healthcare stock.
  • Over the past 92 months, EIGR's price/sales ratio has gone NA NA.
  • EIGR's EV/EBIT ratio has moved down 5.1 over the prior 92 months.

Below are key valuation metrics over time for EIGR.

Stock Date P/S P/B P/E EV/EBIT
EIGR 2021-08-31 48.1 2.5 -11.3 -11.7
EIGR 2021-08-30 47.0 2.5 -11.1 -11.4
EIGR 2021-08-27 47.5 2.5 -11.2 -11.5
EIGR 2021-08-26 46.2 2.4 -10.9 -11.2
EIGR 2021-08-25 46.7 2.5 -11.0 -11.3
EIGR 2021-08-24 46.7 2.5 -11.0 -11.3

EIGR Growth Metrics

    The 5 year net income to common stockholders growth rate now stands at -82.55%.
  • Its 2 year cash and equivalents growth rate is now at -31.94%.
  • Its 3 year net cashflow from operations growth rate is now at -76.37%.
Over the past 34 months, EIGR's revenue has gone up $12,142,000.

The table below shows EIGR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 12.142 -71.342 -33.917
2021-09-30 8.782 -70.092 -30.955
2021-06-30 5.743 -64.94 -24.412
2021-03-31 3.646 -60.378 -20.564
2020-12-31 0 -63.185 -65.051
2020-09-30 0 -62.641 -63.165

EIGR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EIGR has a Quality Grade of F, ranking ahead of 1.43% of graded US stocks.
  • EIGR's asset turnover comes in at 0.037 -- ranking 341st of 682 Pharmaceutical Products stocks.
  • ATNM, MNOV, and ATRA are the stocks whose asset turnover ratios are most correlated with EIGR.

The table below shows EIGR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.037 0.944 -0.198
2021-03-31 0.026 0.985 -0.184
2020-12-31 0.000 NA -0.662
2020-09-30 0.000 NA -0.741
2020-06-30 0.000 NA -0.740
2020-03-31 0.000 NA -0.691

EIGR Price Target

For more insight on analysts targets of EIGR, see our EIGR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.33 Average Broker Recommendation 1 (Strong Buy)

EIGR Stock Price Chart Interactive Chart >

Price chart for EIGR

EIGR Price/Volume Stats

Current price $6.45 52-week high $10.02
Prev. close $6.60 52-week low $3.53
Day low $6.43 Volume 186,354
Day high $6.65 Avg. volume 772,457
50-day MA $7.52 Dividend yield N/A
200-day MA $6.43 Market Cap 278.74M

Eiger BioPharmaceuticals, Inc. (EIGR) Company Bio

Eiger BioPharmaceutical Inc, formerly Celladon Corporation, is a clinical-stage biotechnology company engaged in the development of cardiovascular gene therapy. The company was founded in 2008 and is based in Palo Alto, California.

EIGR Latest News Stream

Event/Time News Detail
Loading, please wait...

EIGR Latest Social Stream

Loading social stream, please wait...

View Full EIGR Social Stream

Latest EIGR News From Around the Web

Below are the latest news stories about Eiger BioPharmaceuticals Inc that investors may wish to consider to help them evaluate EIGR as an investment opportunity.

Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, March 10, 2022 at 4:30 PM ET to discuss its fourth quarter and full year 2021 financial results and provide a business update.

Yahoo | February 24, 2022

What Kind Of Investors Own Most Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)?

If you want to know who really controls Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ), then you'll have to look at the...

Yahoo | February 14, 2022

Pflug Koory, LLC Buys Vertex Pharmaceuticals Inc, Amgen Inc, NVIDIA Corp, Sells Adobe Inc, ...

Investment company Pflug Koory, LLC (Current Portfolio) buys Vertex Pharmaceuticals Inc, Amgen Inc, NVIDIA Corp, Altria Group Inc, Wynn Resorts, sells Adobe Inc, Domtar Corp, AT&T Inc, BTC BlackRock Short Maturity Bond ETF, American States Water Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Pflug Koory, LLC.

Yahoo | January 20, 2022

Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today provided the company's outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones.

Yahoo | January 6, 2022

Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that David Cory, President and CEO, will provide a corporate update at the H.C. Wainwright BioConnect 2022 Virtual Conference.

Yahoo | January 3, 2022

Read More 'EIGR' Stories Here

EIGR Price Returns

1-mo -2.71%
3-mo 51.76%
6-mo -1.07%
1-year -17.73%
3-year -43.52%
5-year -6.52%
YTD 24.28%
2021 -57.77%
2020 -17.52%
2019 46.65%
2018 -27.17%
2017 19.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7183 seconds.